Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to 89.2%) at 24 months in patients with relapsed or refractory multiple myeloma. The study showed a 72% reduction in disease progression or death risk compared to standard treatment. These results mark the first Phase 3 evidence of a GPRC5D bispecific antibody combination's effectiveness earlier in treatment, potentially expanding therapeutic options. Johnson & Johnson is pursuing regulatory approvals to bring this combination to patients globally.
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed...
Johnson & Johnson continues to attract investors with its leaner business model focused on innovative medicine and medical technology after spinning off Kenvue. The company raised its dividend by 3.1%, marking 64 years of consecutive growth, supporte...
With interest rates stabilizing in mid-2026, investors are focusing on Dividend Kings and Aristocrats known for decades of consecutive dividend increases. Johnson & Johnson, Coca-Cola, and McDonald's stand out for their strong Q1 earnings, reasonable...
The SNPD ETF focuses on companies with long histories of increasing dividends, such as Johnson & Johnson, Coca-Cola, Procter & Gamble, PepsiCo, and Lowe's. These companies have strong free cash flow coverage supporting their payouts, making SNPD's di...
